StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
4
Publishing Date
2021 - 12 - 22
2
2021 - 11 - 01
1
2021 - 10 - 29
1
Sector
Health technology
4
Tags
Agreement
8
Alzheimer's
10
America
67
Antibody
8
Application
8
Approval
13
Biosimilar
32
Breast
13
Business
9
Cancer
91
Cell
9
Chmp
10
Diabetes
15
Diagnostics
17
Disease
61
Drug
85
Earnings
18
Europe
15
Expansion
10
Expected
35
Eye
15
Fda
22
Financial
24
Global
228
Growing
43
Growth
235
Health
19
Immunotherapy
11
Infection
9
Kisqali
11
Leukemia
10
Liver
11
Market
592
N/a
945
Novartis
132
People
13
Pharma
13
Pharmaceuticals
17
Pipeline
12
Positive
15
Potential
10
Reach
34
Report
194
Research
118
Respiratory
11
Results
38
Risk
10
Sales
9
Sclerosis
13
Set
15
Study
15
T-cell
11
Technology
12
Therapeutics
109
Therapy
64
Treatment
113
Trial
16
Update
10
Vaccine
10
Year
12
Entities
Alnylam pharmaceuticals, inc.
1
Novartis ag
4
Symbols
A
2
ABBV
8
ABT
4
ADMA
7
AMGN
4
AMPH
2
ANIP
2
AVEO
3
AXNX
2
AZN
3
BBIO
2
BCRX
4
BHC
3
BIIB
3
BMY
5
BNTX
2
BPMC
2
BSX
2
CARA
2
CLSD
2
CNSP
2
CTSO
2
ETON
2
GE
2
GH
3
GILD
3
GMAB
2
GSK
2
GTHX
2
HALO
2
HRTX
2
INCY
2
ITCI
2
JAZZ
3
JNJ
18
KMDA
2
KMPH
4
KPTI
3
LLY
8
LMNL
2
LNTH
2
MBRX
2
MDT
10
MGNX
2
MRK
8
MYOV
2
NVRO
3
NVS
8
NVSEF
4
ORMP
2
PFE
6
PLXP
2
QGEN
2
REGN
3
SENS
2
SNY
16
SRPT
2
TAK
2
TMDX
2
TMO
2
Exchanges
Nasdaq
4
Nyse
4
Crawled Date
2021 - 12 - 23
1
2021 - 12 - 22
1
2021 - 11 - 01
1
2021 - 10 - 29
1
Crawled Time
01:00
1
15:00
1
20:00
1
23:00
1
Source
www.biospace.com
2
www.globenewswire.com
2
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Fda approval
symbols :
NVSEF
save search
Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis
Published:
2021-12-22
(Crawled : 01:00)
- globenewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
9.13%
|
O:
1.23%
H:
0.0%
C:
0.0%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
7.84%
|
O:
0.56%
H:
0.43%
C:
-0.15%
cosentyx
novartis
treatment
fda
fda approval
approval
children
Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
Published:
2021-12-22
(Crawled : 23:00)
- biospace.com/
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
8.25%
|
O:
-0.55%
H:
0.99%
C:
0.92%
ALNY
|
News
|
$144.315
-0.58%
-0.59%
700K
|
Health Technology
|
-27.27%
|
O:
-5.24%
H:
2.44%
C:
-0.93%
leqvio
fda
fda approval
approval
FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
Published:
2021-11-01
(Crawled : 15:00)
- biospace.com/
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
11.47%
|
O:
-0.42%
H:
0.0%
C:
0.0%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
12.47%
|
O:
1.3%
H:
0.0%
C:
0.0%
treatment
fda
myeloid leukemia
leukemia
fda approval
FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
Published:
2021-10-29
(Crawled : 20:00)
- globenewswire.com
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
Email alert
Add to watchlist
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
Email alert
Add to watchlist
treatment
fda
myeloid leukemia
leukemia
fda approval
Gainers vs Losers
67%
33%
Top 10 Gainers
AGBA
|
News
|
$1.26
215.0%
68.25%
130M
|
Finance
EGOX
|
$0.0515
43.06%
30.1%
330M
|
OLB
4
|
$0.33
-14.95%
25.53%
840K
|
Technology Services
NVFY
|
$2.77
31.28%
23.83%
33M
|
Consumer Durables
ZCMD
|
$1.87
28.97%
22.46%
31M
|
Commercial Services
RCON
|
$0.1112
13.01%
21.28%
1.7M
|
Distribution Services
INSG
|
$3.03
25.21%
20.13%
330K
|
Electronic Technology
GCTK
|
$0.8191
22.25%
18.2%
190K
|
Manufacturing
WLGS
|
News
|
$0.59
18.0%
17.9%
2.3M
|
ASNS
|
$0.828
21.75%
17.86%
18K
|
Your saved searches
Save your searches and get alerts when important news are released.